Search
Monobenzone
go.drugbank.com/drugs/DB00600ApprovedWithdrawnIt exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.
Interferon alfa-2a
go.drugbank.com/drugs/DB00034ApprovedInvestigationalWithdrawnAn oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalsusceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but … As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalAsparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999].
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalVIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name
Xamoterol
go.drugbank.com/drugs/DB13781ApprovedIt modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Phenol
go.drugbank.com/drugs/DB03255ApprovedInvestigationalIt is active against a wide range of micro-organisms including some fungi and viruses, but is only slowly effective against spores. Phenol has been used to disinfect skin and to relieve itching. … During the second world war, phenol injections were used as a means of execution by the Nazis. Phenol is a toxic compound whose vapours are corrosive to the skin, eyes, and respiratory tract.
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.